Bristol-Myers Squibb (BMY) vs Pfizer (PFE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bristol-Myers Squibb (BMY) has outperformed Pfizer (PFE) over the past year, gaining 33.7% versus a gain of 6.6%. Over five years, BMY leads with a +2.3% price change compared with -32.5% for PFE. Pfizer is the larger company by market cap ($158.56 billion vs $121.70 billion), about 1.3 times the size, while Bristol-Myers Squibb is growing revenue faster (-0.2% vs -1.6%).
On valuation, Bristol-Myers Squibb trades at a lower forward P/E (9.0x vs 9.6x for Pfizer). Pfizer offers the higher dividend yield (6.18% vs 4.21%). Bristol-Myers Squibb converts more of its revenue into profit, with a net margin of 14.6% versus 12.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMY | PFE |
|---|---|---|
| Share price | $59.58 | $27.82 |
| Market cap | $121.70B | $158.56B |
| 1-day change | -0.20% | -0.64% |
| YTD return | +10.68% | +12.45% |
| 1-year return | +33.68% | +6.59% |
| 5-year return | +2.30% | -32.51% |
| P/E ratio (TTM) | 13.12 | 36.61 |
| Forward P/E | 9.02 | 9.60 |
| EPS (TTM) | $4.54 | $0.76 |
| Dividend yield | 4.21% | 6.18% |
| Annual dividend | $2.51 | $1.72 |
| Revenue (latest FY) | $48.19B | $62.58B |
| Revenue growth (YoY) | -0.22% | -1.65% |
| Net income (latest FY) | $7.05B | $7.77B |
| Gross margin | 71.08% | 74.33% |
| Net margin | 14.64% | 12.42% |
| 52-week high | $68.64 | $29.21 |
| 52-week low | $42.52 | $23.62 |
| Distance from 52-week high | -13.20% | -4.76% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +11.06% | +3.92% |
| Average volume | 11.22M | 35.94M |
| Shares outstanding | 2.04B | 5.70B |
| Employees | 32,500 | 75,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BMY has outperformed PFE by 27.1 percentage points over the past year.
- Pfizer trades at a higher earnings multiple (36.6x vs 13.1x trailing P/E).
- Pfizer offers a meaningfully higher dividend yield (6.18% vs 4.21%).
About Bristol-Myers Squibb
BMY stock →Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 32,500 employees
About Pfizer
PFE stock →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees
BMY vs PFE FAQ
Which is bigger, Bristol-Myers Squibb or Pfizer?
Pfizer (PFE) is larger, with a market capitalization of $158.56B compared with $121.70B for Bristol-Myers Squibb (BMY).
Which stock has performed better over the past year, BMY or PFE?
BMY returned +33.68% over the past 12 months, compared with +6.59% for PFE (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BMY or PFE?
BMY has the lower trailing P/E at 13.1, versus 36.6 for PFE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Bristol-Myers Squibb or Pfizer?
Pfizer has the higher yield at 6.18%, compared with 4.21% for Bristol-Myers Squibb.
Are Bristol-Myers Squibb and Pfizer in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.